PHI Cloud Pen Testing. Built for Connected Devices.
Targeted cloud backend testing for connected medical devices that store or transmit PHI: APIs, IAM, tenant isolation, KMS, and IoT brokers. HIPAA-aligned, FDA reviewer-ready, and SOC 2 evidence-grade.
The short answer
What is cloud backend penetration testing for connected medical devices?
Cloud backend penetration testing checks the servers, APIs, storage and identity setup that a connected device or its app talks to, especially where patient data (PHI) is stored or sent. Testers look for broken access control, exposed data, weak authentication, cloud misconfiguration and ways to reach the device through the cloud. The report supports both FDA submissions and HIPAA risk analysis.
AWS · Azure · GCP. HIPAA + FDA + SOC 2 evidence in one engagement.
- Device-to-cloud APIs
- IAM & tenant isolation
- KMS & secrets
- MQTT / IoT brokers
- Free 30-min scoping call
- Fixed-fee quote in 24 hours
- Senior cloud + healthcare specialist
- AWS / Azure / GCP coverage
- Re-test included
Fixed-fee engagement
PHI cloud backend penetration testing: deliverables, inputs, and exclusions
Included work is defined in the signed proposal. These scope options are not automatic inclusions in every engagement.
Fixed-fee deliverables
- Agreed device-to-cloud APIs, identity, tenancy, storage, encryption, broker interfaces, and PHI exposure checks.
- A Penetration Test Plan, Test Cases, and Test Report for the agreed attack surface and product versions.
- Documented findings, reproduction evidence, and remediation recommendations. Clean test cases and agreed retest evidence. Device tests trace to documented threats. They distinguish security impact from manufacturer-supplied patient-harm context.
Required inputs
- Cloud architecture, IAM roles, storage/service inventory, PHI data-flow diagrams, test tenants, and non-production test data.
- Written authorization, rules of engagement, in-scope targets and versions, test windows, and an escalation contact.
- Test accounts, environment access, architecture and data-flow information, and known access restrictions. Device work also needs intended use, available threat model, and ISO 14971 hazard context.
Exclusions and separate work
- Unlisted targets, production disruption, destructive hardware work, and third-party systems without authorization are excluded. Additional interfaces require agreement.
- SBOM generation, SAST, threat-model creation, and architecture views are separate unless explicitly bundled. A targeted test is not whole-device coverage.
- General software verification and validation, clinical performance testing, and full QMS implementation or certification are outside Blue Goat's product cybersecurity scope.
- The manufacturer retains engineering changes, clinical-risk evaluation, risk acceptance, release approval, and regulatory submission decisions. No regulatory outcome is promised.
Pricing and scope changes
A written fixed-fee quote after scoping. The proposal names deliverables, versions, assumptions, required inputs, exclusions, and agreed dates. Additional work requires a separately agreed scope change. Missing inputs, access restrictions, manufacturer fixes, and review feedback can affect delivery.
FDA guidance: Cybersecurity Testing, Section C
Cybersecurity testing beyond standard software V&V
The FDA recommends cybersecurity testing in a security context, beyond standard software verification and validation. Security testing documentation and associated reports or assessments should be included in the premarket submission. Penetration testing is one part of this evidence, not a substitute for every testing activity.
The manufacturer retains design verification and validation procedures under ISO 13485 Subclauses 7.3.6 and 7.3.7, design input and output review, fixes, risk acceptance, and release decisions. Blue Goat provides scoped cybersecurity testing and evidence, not general software V&V or software validation services.
Security requirements and boundaries
The FDA recommends evidence that each security design input was implemented successfully, plus boundary analysis and the rationale for boundary assumptions. Our agreed test cases connect applicable security requirements, threats, expected secure behavior, and actual results. Exclusions and untested requirements remain visible.
Threat-mitigation effectiveness
Testing evidence should address risk controls represented in the Global System, Multi-Patient Harm, Updatability and Patchability, and Security Use Case security architecture views. The threat model and Threat Table are separate deliverables, linked to controls and test evidence. Review security-policy enforcement and, as appropriate, maximum-traffic performance, stability, and reliability. The proposal identifies included checks and other manufacturer evidence needed.
Vulnerability testing and analysis
Section C references ANSI/ISA 62443-4-1 and recommends considering the following testing and analysis evidence:
- Abuse or misuse cases, malformed and unexpected inputs, robustness, and fuzz testing.
- Attack surface analysis and vulnerability chaining.
- Closed-box known-vulnerability scanning.
- Software composition analysis of binary executable files.
- Static and dynamic code analysis, including hardcoded, default, easily guessed, or easily compromised credentials.
This is a guidance evidence checklist, not a promise that every method is included in standalone penetration testing. SAST, binary software composition analysis, SBOM work, and threat-model creation or rework are separate unless explicitly bundled. Other methods depend on agreed access, interfaces, risks, and scope. Automated scan output alone is not a penetration test.
Penetration-test evidence
Adversarial tests focus on discovering and exploiting product vulnerabilities to identify and characterize security-related issues. The FDA recommends providing penetration-test reports that include:
- Independence and technical expertise of testers.
- Scope of testing.
- Duration of testing.
- Testing methods employed.
- Test results, findings, and observations.
Our Test Plan, Test Cases, and Test Report connect scope, methods, requirements, threats, findings, clean results, limitations, and retests. Documented evidence does not establish regulatory acceptance or replace manufacturer review.
Source: Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, February 3, 2026, Section C. Guidance recommendations are distinct from Section 524B statutory duties.
Why Generic Cloud Pen Tests Miss the Real Risk
A standard cloud pen test focuses on a web app and its REST API. Connected medical devices add a device-to-cloud channel, multi-tenant data isolation, and PHI handling: risks generic engagements aren't scoped for.
Device Channel Untouched
MQTT brokers, IoT Core, and device certificates are different from a web API. Most pen tests skip them entirely.
No Tenant-Isolation Testing
Cross-tenant data leakage is the #1 risk for multi-org platforms. It requires a deliberate test matrix, not a single-account scan.
HIPAA Mapped, Not Tested
Generic firms hand you a HIPAA mapping spreadsheet. We test whether the technical safeguards actually hold under attack.
What We Actually Test
Scope is à la carte: pick the cloud surfaces in your device's backend. We can assess one cloud or all three.
Device-to-Cloud Channel
- Device authentication (X.509, JWT, mutual TLS)
- Certificate provisioning and rotation flow
- MQTT / AMQP topic ACLs and wildcards
- AWS IoT Core / Azure IoT Hub / GCP IoT Core review
- Replay, spoof, and rogue-device scenarios
API & Authorization
- REST / GraphQL endpoint enumeration
- Object-level authZ (BOLA / IDOR) at scale
- Function-level authZ (BFLA) and role boundaries
- Token lifecycle, refresh, and revocation
- Rate-limit, mass-assignment, and SSRF
Tenant Isolation & PHI
- Cross-tenant data access matrix
- Org-boundary leakage in shared resources (queues, caches)
- PHI data-flow trace from device to storage to UI
- PHI in logs, metrics, and error responses
- Backup, snapshot, and export-path PHI exposure
Cloud Infrastructure & Secrets
- IAM least-privilege audit (AWS / Azure / GCP)
- KMS / Key Vault / Cloud KMS key policy review
- S3 / Blob / GCS bucket exposure and misconfig
- Lambda / Functions / Cloud Run inspection
- Secrets in code, config, and CI/CD pipelines
- VPC, security group, and network ACL review
Engagement Methodology
Three to five weeks. Read-only IAM access in your non-prod (or prod, with safeguards) accelerates everything.
- 01
Scoping & Architecture Review
We review your cloud architecture, PHI data-flow diagram, threat model, and HIPAA risk analysis. We agree on environment (staging vs. prod), test windows, and PHI-handling rules.
- 02
Reconnaissance & Configuration Review
Read-only IAM audit, infrastructure-as-code review where available, and external attack-surface enumeration. We map every PHI-touching service.
- 03
Active Testing
API authZ matrix, device-channel attacks, tenant-isolation probing, secrets hunting, and PHI exposure tracing. All testing scoped to avoid PHI exfiltration: synthetic accounts only where possible.
- 04
FDA + HIPAA + SOC 2 Reporting
Findings mapped to FDA Feb 2026 guidance, HIPAA Security Rule technical safeguards, and SOC 2 CC controls. One report, three evidence packages. Re-test included.
Reviewer-ready deliverables in one engagement
Every engagement ships with documented artifacts, traceable, complete, and aligned with current guidance.
- Device-to-cloud API authentication and authZ
- Tenant isolation and multi-org boundary testing
- AWS/Azure/GCP IAM, KMS, and storage misconfig review
- PHI data-flow tracing and exposure analysis
- HIPAA technical safeguard validation
- MQTT, AMQP, and IoT broker abuse cases
Pricing Guidance
Fixed-fee. Cloud scope scales with surface area, not just lines of code.
Single-Cloud, Single-Tenant
Fixed fee after scoping
One cloud (AWS or Azure or GCP), single-tenant deployment, modest API surface, no IoT broker or limited MQTT scope.
- API authZ matrix (up to ~30 endpoints)
- IAM + KMS + storage configuration review
- PHI data-flow trace
- HIPAA technical-safeguard validation
- One round of re-test
Multi-Tenant SaaS
Fixed fee after scoping
Most connected-device platforms: multi-tenant, device-to-cloud channel, ~50-150 API endpoints, IoT Core / IoT Hub in scope.
- Full tenant-isolation matrix
- Device-channel + MQTT topic ACL testing
- Cross-tenant PHI exposure probing
- IaC review (Terraform / CDK / Bicep) where available
- Two rounds of re-test
Multi-Cloud / Enterprise
Fixed fee after scoping
Multi-cloud or hybrid deployments, enterprise IDP federation, complex data-residency requirements, or high-volume IoT fleets.
- Per-cloud configuration audit
- Federated identity + SSO boundary testing
- Data-residency and cross-region PHI flow review
- Dedicated senior cloud + healthcare lead
What drives the price
- Number of clouds in scope (AWS / Azure / GCP)
- Number of API endpoints and microservices
- Multi-tenancy model (shared schema, schema-per-tenant, account-per-tenant)
- Device-channel protocol (HTTPS, MQTT, AMQP, custom)
- Test environment (production with safeguards vs. staging clone)
- Whether infrastructure-as-code is available for review
- PHI volume and data-residency constraints
Production testing is supported with PHI-safe test accounts and rate-limit coordination. We never exfiltrate real PHI.
PHI Cloud Backend Pen Testing FAQs
Cybersecurity alerts and guides
Goat's Weekly alerts
Medical device advisories and safety communications, with links to original sources. An alert is a reason to assess applicability, not proof that your device is affected.
Threat modeling, eSTAR 7.1, and SBOM evidence
Connect threats to controls and test evidence. Compare the CISA 2026 SBOM fields with the NTIA 2021 baseline the FDA still cites, plus its support fields. Guidance recommendations remain separate from statutory duties.
PHI Cloud Backend Penetration Testing - scoped, fixed-fee, built for FDA premarket submissions.
Targeted cloud backend testing for connected medical devices that store or transmit PHI: APIs, IAM, tenant isolation, KMS, and IoT brokers. HIPAA-aligned, FDA reviewer-ready, and SOC 2 evidence-grade.
